Metraipolis › archive › dc_d995a76afd05

Long-term outcomes of venetoclax and ibrutinib in Japanese patients with relapsed/refractory mantle cell lymphoma — Europe PMC PMID:40897939

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/40897939
DOI
10.1007/s10147-[numero omesso]-4
License (as archived)
solo-consultazione
Archived
2026-10-08T08:10:19.692Z
SHA-256 of the archived text
4f4c2aef549f61c5508e06a43e45afea44ff9d389eaf3e216677a5807d2135de
Stable URL of this page
https://metraipolis.com/documento/dc_d995a76afd05

How to cite

Long-term outcomes of venetoclax and ibrutinib in Japanese patients with relapsed/refractory mantle cell lymphoma — Europe PMC PMID:40897939 — Europe PMC (en), https://europepmc.org/article/MED/40897939 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_d995a76afd05 (Metraipolis archive dc_d995a76afd05, sha256 4f4c2aef549f61c5508e06a43e45afea44ff9d389eaf3e216677a5807d2135de)
BibTeX
@misc{dcd995a76afd05,
  title = {Long-term outcomes of venetoclax and ibrutinib in Japanese patients with relapsed/refractory mantle cell lymphoma — Europe PMC PMID:40897939},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/40897939},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_d995a76afd05; sha256 4f4c2aef549f61c5508e06a43e45afea44ff9d389eaf3e216677a5807d2135de},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/40897939. Agents can read the archived copy with the MCP tool read_document.